Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REJOICE-Ovarian05: Raludotatug Deruxtecan With or Without Bevacizumab Versus Platinum Doublet Chemotherapy With or Without Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer After First-Line PARP Inhibitor Maintenance
MOH_2026-08-13_016983Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of raludotatug deruxtecan in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
raludotatug deruxtecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on MOH_2026-08-13_016983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-13_016983.